Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.9% - What's Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) was down 5.9% during trading on Friday . The stock traded as low as $17.88 and last traded at $17.99. Approximately 198,289 shares changed hands during mid-day trading, a decline of 53% from the average daily volume of 422,191 shares. The stock had previously closed at $19.12.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BCAX shares. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. HC Wainwright started coverage on shares of Bicara Therapeutics in a research report on Friday, December 6th. They set a "buy" rating and a $42.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating on the stock. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price target for the company. Finally, TD Cowen initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics has an average rating of "Buy" and an average target price of $43.00.

Bicara Therapeutics Stock Down 4.4 %

The firm's 50 day moving average price is $20.72.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, equities analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently added to or reduced their stakes in BCAX. RA Capital Management L.P. acquired a new position in Bicara Therapeutics in the third quarter valued at about $177,169,000. FMR LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $57,913,000. Braidwell LP acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $42,219,000. Janus Henderson Group PLC bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $30,329,000. Finally, Baker BROS. Advisors LP acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.